Quoin Pharmaceuticals (2EB0) Ratios
Quoin Pharmaceuticals Ratios
DE:2EB0's free cash flow for Q2 2026 was $-3.21M. For the 2026 fiscal year, DE:2EB0's free cash flow was decreased by $-3.00 and operating cash flow was $-3.21M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.61 | 3.57 | 3.15 | 3.79 | 1.79 |
| Quick Ratio | 3.61 | 3.57 | 3.15 | 3.79 | 1.79 |
| Cash Ratio | 688.33 | 0.87 | 0.67 | 0.81 | 1.64 |
| Solvency Ratio | -2.16 | -1.36 | -1.32 | -1.32 | -2.46 |
| Operating Cash Flow Ratio | -2.44 | -1.88 | -2.20 | -2.40 | -1.25 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 12.74M | $ 8.42M | $ 4.78M | $ 6.32M | $ -501.57K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.55 | 1.71 | 2.15 | 1.95 | 14.24 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -11.99 | -18.59 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -12.96 | -5.56 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 1.77 | 682.79 |
| Net Debt to EBITDA | 243.12 | 0.41 | 0.26 | 0.33 | 0.37 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.02% | 94.06% | 92.62% | 101.34% | 354.00% |
| Return on Assets (ROA) | -77.51% | -57.05% | -71.38% | -64.89% | -229.38% |
| Return on Equity (ROE) | -120.47% | -97.37% | -153.36% | -126.66% | -3266.60% |
| Return on Capital Employed (ROCE) | -109.75% | -82.65% | -109.21% | -84.70% | -126.82% |
| Return on Invested Capital (ROIC) | -109.75% | -82.65% | -109.21% | -84.70% | -126.82% |
| Return on Tangible Assets | 4.35% | -58.86% | -74.98% | -68.21% | -251.08% |
| Earnings Yield | -73.10% | -293.69% | -196.56% | -3.89% | -140.65% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -9.04 | -58.65 | -305.52 | -21.00 | -3581.77 |
| Free Cash Flow Per Share | -9.04 | -58.65 | -305.52 | -21.62 | -3973.13 |
| Dividend Paid and CapEx Coverage Ratio | -3385248.50 | 0.00 | -2088357.06 | -0.13 | -9.15 |
| Capital Expenditure Coverage Ratio | -3385248.50 | 0.00 | -2088357.06 | -33.92 | -9.15 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -62.63% | -257.47% | -177.96% | -3.62% | -41.58% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.36 | -0.34 | -0.51 | -25.68 | -0.71 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.65 | 0.33 | 0.78 | 32.52 | 23.22 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.60 | -0.39 | -0.56 | -27.59 | -2.40 |
| Price-to-Operating Cash Flow Ratio | -1.60 | -0.39 | -0.56 | -28.40 | -2.67 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.00 | -0.00 | 0.26 | -0.00 |
| Enterprise Value Multiple | 241.74 | 0.06 | -0.22 | -27.79 | -0.38 |
| Enterprise Value | -3.80B | -571.64K | 2.02M | 238.02M | 7.78M |
| EV to EBITDA | 241.74 | 0.06 | -0.22 | -27.79 | -0.38 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 280.37 | 0.07 | -0.26 | -27.26 | -1.23 |
| EV to Operating Cash Flow | 280.37 | 0.07 | -0.26 | -28.07 | -1.36 |
| Tangible Book Value Per Share | -247.09 | 65.10 | 197.38 | 16.59 | -94.91 |
| Shareholders’ Equity Per Share | 8.76 | 68.71 | 220.04 | 18.34 | 411.42 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -10.55 | -66.90 | -337.46 | -23.23 | -13439.32 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.93 | 1.08 | 1.05 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.85 | 0.87 | 0.91 | 0.90 | 0.27 |
Currency in USD